Katherine Tweden - ReShape Lifesciences Insider

ETRM -- USA Stock  

USD 2.05  0.07  3.54%

Dr. Katherine S. Tweden, Ph.D., was promoted as Senior Vice President Research of the Company. She was the Vice President Clinical and Regulatory of EnteroMedics Inc., since May 2011. Prior to that Dr. Tweden served as our Vice President of Research and Clinical from September 2008 to May 2011 and our Vice President of Research from January 2003 to September 2008. From November 2002 to January 2003, Dr. Tweden was a consultant to Venturi Group, a medical device incubator company. From January 2003 through August 2004, Dr. Tweden worked for Venturi Development Inc. as a consultant to us. From July 1997 to October 2002, Dr. Tweden held positions including Director of Research and Vice President of Research for HeartStent Corporationrationration. From September 1990 to June 1997, Dr. Tweden held the positions of Senior Research Scientist and Principal Research Scientist at St. Jude Medical, Inc
Age: 53  Founder Since 2015      
651-634-3003  http://www.enteromedics.com
Tweden received a Bachelor of Arts in chemistry from Gustavus Adolphus College and a Master?s degree and Ph.D. in biomedical engineering from Iowa State University.

Management Efficiency

The company has return on total asset (ROA) of (48.42) % which means that it has lost $48.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (146.32) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. ReShape Lifesciences (ETRM) is traded on Nasdaq Capital Markets in USA. It is located in St. Paul, MN and employs 37 people.

ReShape Lifesciences Leadership Team

Jon Tremmel, Consultant To The CEO and Director
Peter Delange, Senior Vice President - Operations and Business Development
Scott Youngstrom, CFO, Chief Compliance Officer
Dan Gladney, CEO and President and Director
Nicholas Teti, Independent Director
Carl Goldfischer, Independent Director
Catherine Friedman, Independent Director
Michael Mashaal, Director
Lori McDougal, Director
Gary Blackford, Director
Nick Ansari, Senior Vice President - Sales
Scott Shikora, Executive Vice President - Medical Affairs and Chief Medical Officer
Anthony Jansz, Director
Adrianus Donders, Sr. VP of Research and Advanced Devel.
Katherine Tweden, Co-Founder and VP of Clinical and Regulatory
Mark Knudson, Founder and Executive Chairman
Gregory Lea, CFO, Principal Accounting Officer, Chief Compliance Officer and Secretary
Paul Hickey, Senior Vice President - Marketing and Reimbursement
Bobby Griffin, Independent Director
Tonya Dowd, Vice President - Reimbursement
Naqeeb Ansari, Senior Vice President - Sales

Stock Performance Indicators

Did you try this?

Run Analyst Recommendations Now

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Analyst Recommendations

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for ReShape Lifesciences and Stryker. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.